Get started
Author

Lucia Morello

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms
2013 · Marzia Varettoni, Luca Arcaini, et al. · Blood · 342
PDF
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms
2011 · Luca Arcaini, Silvia Zibellini, et al. · Blood · 168
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
2020 · Carlo Visco, Alice Di Rocco, et al. · Leukemia · 107
PDF
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection
2014 · L. Arcaini, D. Rossi, et al. · Haematologica · 84
PDF
Time to progression of mantle cell lymphoma after high‐dose cytarabine‐based regimens defines patients risk for death
2018 · Carlo Visco, Maria C. Tisi, et al. · British Journal of Haematology · 74
PDF
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
2022 · Chiara Rusconi, Chan Y. Cheah, et al. · Blood · 48
PDF
Assessment of bone marrow involvement in non‐Hodgkin’s lymphomas: comparison between histology and flow cytometry
2010 · Michele Merli, Luca Arcaini, et al. · European Journal Of Haematology · 33
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network
2019 · Sara Rattotti, Virginia Valeria Ferretti, et al. · Hematological Oncology · 29
PDF
Distinctive Clinical and Histological Features of Waldenström's Macroglobulinemia and Splenic Marginal Zone Lymphoma
2011 · Luca Arcaini, Marzia Varettoni, et al. · Clinical Lymphoma Myeloma & Leukemia · 29
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
2019 · Carmelo Carlo-Stella, Richard Delarue, et al. · Clinical Lymphoma Myeloma & Leukemia · 28
Chemotherapy after PD ‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
2022 · Eleonora Calabretta, Anna Guidetti, et al. · British Journal of Haematology · 23
PDF
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
2024 · Francesca Romana Mauro, Potito Rosario Scalzulli, et al. · Cancers · 21
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
2024 · Chiara Malinverni, Andrea Bernardelli, et al. · Blood · 20
Mantle Cell Lymphoma of Mucosa‐Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
2019 · Lucia Morello, Sara Rattotti, et al. · HemaSphere · 19
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
2018 · Alessandro Broccoli, Beatrice Casadei, et al. · Oncotarget · 17
PDF
Outcomes in First Relapsed‐refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle‐first Study
2019 · C. Visco, A. Di Rocco, et al. · Hematological Oncology · 12
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi
2021 · Annalisa Arcari, Lucia Morello, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
Autologous stem cell transplantation with in vivo purged progenitor cells shows long‐term efficacy in relapsed/refractory follicular lymphoma
2014 · Luca Arcaini, Lucia Morello, et al. · American Journal of Hematology · 10
PDF
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
2024 · Danilo De Novellis, Daniele Derudas, et al. · European Journal Of Haematology · 9
PDF
The BRAF V600E Mutation in Hairy Cell Leukemia and Other Mature B-Cell Neoplasms
2011 · Luca Arcaini, Silvia Zibellini, et al. · Blood · 9
Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
2019 · Martina Di Trani, Ettore Rizzo, et al. · Blood · 7
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment
2024 · Annalisa Arcari, Lucia Morello, et al. · Cancers · 6
PDF
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
2025 · Ernesto Vigna, Enrica Antonia Martino, et al. · Hematological Oncology · 5
SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI‐CENTER STUDY
2017 · C. Carlo‐Stella, P. Barde, et al. · Hematological Oncology · 5
PDF
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort
2026 · Enrica Antonia Martino, Annalisa Pitino, et al. · Blood Advances · 4
PDF
Works count: 57
Citation count: 1,150
H-index: 15
I10-index: 18
Year
Topic
Type